Sagent Pharmaceuticals

Spectrum sells off generic drugs

Fri, 09 May 2008 06:59:55 -0400

Specturm Pharmaceuticals has sold its abbreviated NDAs for its injectable generic drugs, ondansetron, carboplatin, fludarabine, and mitoxantrone, to Sagent Pharmaceuticals. Sagent, which made our list of the top 20 VC deals of 2007, brings finished pharmaceutical therapies onto the U.S. market and is focused on injectable products. "The sale of these non-core assets provides additional non-dilutive funding which will be used to further fund the advancement of our late stage clinical programs," said Rajesh C. Shrotriya, Spectrum's CEO. Spectrum has 12 drug candidates in the clinic and three more in preclinical development.

- check out Spectrum's release

Sagent Pharmaceuticals - Top 20 VC deals of 2007

Maureen Martino — Mon, 28 Jan 2008 10:25:38 -0500

Company: Sagent Pharmaceuticals
Based: Schaumburg, IL
Amount: $53M
Round: First
Investors: Capricorn Management, Vivo Ventures

Scoop: Sagent Pharmaceuticals brings finished pharmaceutical therapies onto the U.S. market; it is focused on injectable products. The company currently has more than 200 products in development, with more than 30 submissions to the FDA expected by the end of 2007. Sagent expects to double its FDA submissions in 2008.

More News:
Start-ups snare big rounds of venture funds. Report

Start-ups snare big rounds of venture funds

Thu, 27 Sep 2007 06:59:57 -0400

Sagent Pharmaceuticals has lined up $53 million in venture financing, a big first round for the start-up based in Schaumburg, IL. Vivo Ventures led the round for Sagent, which was launched in 2006.

"This venture funding enables us to quickly advance many of our recent development efforts into near-term commercialization while accelerating development of our extensive pipeline," said Jeffrey M. Yordon, CEO. "We are confident that our strong financial position and experienced management team, combined with the extensive experience and capabilities of our business partners, positions us to achieve rapid success in our target specialty product market."

- check out the release for more info

ALSO: Sequel Pharmaceuticals has garnered $20 million in first round funds to develop an experimental therapy for atrial fibrillation that was spun out of NovaCardia after that company was acquired by Merck. Sequel's management is looking to in-license other cardiovascular drugs. Previous NovaCardia investors Domain Associates, Forward Ventures, InterWest Partners, Montreux Equity Partners, and Skyline Ventures participated in the Series A. Release